AAV NDP Gene Therapy for NDP-Related Diseases Including Norrie Disease and Retinopathy
Summary
USPTO published patent application US20260091131A1 by University of Massachusetts inventors disclosing AAV constructs encoding wildtype or codon-optimized NDP gene sequences for treating Norrie disease, diabetic maculopathy, retinopathy, and other NDP-related retinal diseases. The application, filed October 10, 2023, covers methods of administration including intravitreal injection for retinal neovascularization and exudation conditions.
What changed
The USPTO published a patent application disclosing AAV (adeno-associated virus) gene therapy constructs containing NDP (noriccin) gene sequences for treating Norrie disease and related beta-catenin signaling retinal diseases. The application claims both wildtype and codon-optimized NDP nucleic acid sequences packaged in AAV particles, along with methods for treating conditions including retinopathy of prematurity, diabetic maculopathy, Coats disease, familial exudative vitreoretinopathy, and age-related hearing loss.
Patent applications are informational publications; they do not impose compliance deadlines or operational requirements on third parties. Biotech companies, pharmaceutical firms, and researchers developing gene therapies for ocular diseases should review this publication for potential freedom-to-operate implications or licensing opportunities.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PRODUCTS AND METHODS FOR USE IN TREATING NDP-RELATED DISEASES
Application US20260091131A1 Kind: A1 Apr 02, 2026
Inventors
Jane SOWDEN, Valda PAUZUOLYTE, James WAWRZYNSKI, Aara PATEL
Abstract
The invention relates to a construct and AAV particle comprising a wildtype NDP nucleic acid sequence or a codon-optimised NDP nucleic acid sequence. The invention further relates to products and methods for the treatment of one or more of Norrie disease, age related hearing loss, diabetic maculopathy and retinopathy, retinal neovascularisation, retinal exudation, retinopathy of prematurity (ROP), Familial exudative vitreoretinopathy (FEVR), Coats disease, and other NDP-related diseases, or other beta catenin signalling-related retinal diseases.
CPC Classifications
A61K 48/005 A61K 9/0019 A61K 9/0048 A61K 48/0075 A61K 48/0083 A61P 27/12 A61P 27/16 C07K 14/475 C12N 15/86 A61K 38/00 C12N 2750/14143 C12N 2750/14145 C12N 2800/22
Filing Date
2023-10-10
Application No.
19120184
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.